Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2150

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2150
---
 stock dividends, stock combinations, recapitalizations and
similar events). The January 2025 Common Warrants are exercisable beginning six months after the issuance date (the “Initial Exercisability
Date”) and expiring on the third anniversary of the Initial Exercisability Date. The January 2025 Common Warrants require “buy-in”
payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise. If at the time of exercise of the
January 2025 Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying the January
2025 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms

During the period from January
1, 2025 to April 10, 2025, 1,098 shares of Series A Preferred Stock were converted into 288,832 shares of Common Stock. The conversion
ratio was based on the Series A Certificate of Designations and reflected the applicable Alternate Conversion Price.

During the period from January
1, 2025 to April 10, 2025, 75 shares of Series B Preferred Stock were converted into 50,001 shares of Common Stock. The conversion ratio
was based on the Series B Certificate of Designations and reflected the applicable Alternate Conversion Price.

F-32

During the period from January
1, 2025 to April 10, 2025, the Company sold 290,618 shares of Common Stock of the Company pursuant to the New Keystone Purchase Agreement
for net proceeds of $1,227,242.

On February 5, 2025, the
Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member
of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 2,551,020 shares of its
common stock, par value $0.0001 per share (the “Common Stock”) or common stock equivalents in lieu thereof; and (ii) common
warrants to purchase up to 2,551,020 shares of common stock (the “Warrants”), at a combined public offering price of $1.96
per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase agreement
(the “SPA”) with the investors. The SPA contains customary representations, warranties and agreements of the Company